9/21/2025

Bristol-Myers Squibb Co. (NYSE:BMY) is an American multinational biopharmaceutical company that develops, manufactures, and markets innovative medicines to help patients with serious diseases. It will report its Q3 2025 earnings on Oct. 30. Wall ...

Source: Yahoo

9/20/2025

So you are staring at Bristol-Myers Squibb's ticker and wondering if now is the time to make a move. When a stock like this shows a long-term downtrend but still dominates conversations in the pharma sector, it's only natural to ask whether the negative sentiment has gone too far. This year alone, shares have slid 20.7%, with a 6.7% decline over the last month and even a dip of 2.6% in the past week. What's driving all the caution, and is Wall Street missing something under the hood? Much of...

Source: Yahoo

9/20/2025

Bristol Myers Squibb is a strong buy, with a 5.5% yield, growth portfolio, and undervalued shares. See here for more analysis on BMY stock.

Source: SeekingAlpha

9/19/2025

Bristol-Myers Squibb Company (NYSE:BMY) is included among the Best Stocks for a Dividend Stock Portfolio. Bristol-Myers Squibb Company (NYSE:BMY) is a pharmaceutical company focused on developing treatments across cancer, blood disorders, cardiovascular disease, immunology, and neuroscience. Its portfolio includes widely recognized therapies such as Opdivo for oncology and Eliquis for preventing blood clots, alongside a […]

Source: Yahoo

9/19/2025

The initiative is part of Trump’s demands that drugmakers reduce their prices to align them with what other developed countries pay, according to the people, who spoke on condition of anonymity to discuss plans that are not yet public. The proposed website would allow patients to search for specific medicines and be connected with platforms that sell them, the people said.

Source: Yahoo

9/19/2025

Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.

Source: Yahoo

9/19/2025

PRINCETON, N.J., September 19, 2025--Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

Source: Yahoo

9/18/2025

In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $45.6, denoting a -1.19% move from the preceding trading day.

Source: Yahoo

9/18/2025

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Source: Yahoo

9/18/2025

Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They have the potential to treat a range of conditions, such as cancer, autoimmune diseases, infectious diseases, urinary issues, spinal cord injuries, joint cartilage damage, immune system weakness, and neurological disorders.

Source: Yahoo

9/18/2025

The Dividend Harvesting Portfolio reached all-time highs, up 34.27% on invested capital. Learn more about the portfolio here.

Source: SeekingAlpha

9/17/2025

Exxon Mobil advances key projects, AMD rides EPYC and AI demand, and Caterpillar gains on Energy & Transportation strength.

Source: Yahoo

9/17/2025

Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and pancreatic cancer remain among the hardest to treat, while rare pediatric disorders still take a tragic toll on young patients each year. Against this backdrop of significant unmet need, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) distinguishes itself. Guided by the forward-looking leadership of chair and CEO Dr. Vuong Trieu

Source: Yahoo

9/17/2025

PRINCETON, N.J., September 17, 2025--Bristol Myers Squibb Announces Dividend

Source: Yahoo

9/17/2025

SHANGHAI (Reuters) -U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China. The spokesperson said Bristol Myers was "committed to supporting all impacted employees" and was "grateful for their contributions", but said it does not comment on transaction details, citing policy. Established in 1982, the Sino-American Shanghai Squibb Pharmaceuticals Limited (SASS) joint venture was the first Sino-U.S. pharmaceutical joint venture in the country.

Source: Yahoo

9/16/2025

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best drug stocks to buy right now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the market, […]

Source: Yahoo

9/16/2025

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Bristol-Myers Squibb Company stands fifth among them. Bristol-Myers Squibb Company (NYSE:BMY), a global biopharmaceutical leader, specializes in oncology, immunology, cardiovascular, hematology, and neuroscience therapies, with blockbuster drugs including Eliquis and Opdivo. In July 2025, Bristol-Myers Squibb Company (NYSE:BMY) […]

Source: Yahoo

9/16/2025

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Source: Yahoo

9/16/2025

K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical need, today provided a clinical update on its lead asset, KTX-1001 for multiple myeloma (MM).

Source: Yahoo

9/16/2025

PRINCETON, N.J., September 16, 2025--Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Source: Yahoo